Mirum Pharmaceuticals, Inc.
MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia diseasā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$73.13
Price+1.91%
$1.37
1Y
Price
Market Cap
$3.609b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+6.8%
EBITDA Margin+2.2%
Net Profit Margin+29.7%
Free Cash Flow MarginRevenue
$471.794m
+40.0%
1y CAGR+87.6%
3y CAGR+141.3%
5y CAGREarnings
-$41.423m
+52.9%
1y CAGR+26.2%
3y CAGR+4.3%
5y CAGREPS
-$0.86
+53.5%
1y CAGR+35.9%
3y CAGR+15.7%
5y CAGRBook Value
$292.046m
$785.115m
Assets$493.069m
Liabilities$318.764m
DebtDebt to Assets
40.6%
-58.1x
Debt to EBITDAFree Cash Flow
$44.318m
+374.9%
1y CAGR+169.8%
3y CAGR+132.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company